366-45-0

Basic information

• Product Name: 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE
• Synonyms: acetamide, 2-chloro-N-(2-fluoro-4-methylphenyl)-;2-chloro-N-(2-fluoro-4-methylphenyl)acetamide
• CAS NO: 366-45-0
• Molecular Formula: C₉H₉ClFNO
• Molecular Weight: 201.6253
• Mol File: 366-45-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 329.6 °C at 760 mmHg
• Flash Point: 153.1 °C
• Appearance: /
• Density: 1.306 g/cm³
• Vapor Pressure: 0.000176mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE(366-45-0)
• EPA Substance Registry System: 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE(366-45-0)

Safety Data

• Hazardous Substances Data: 366-45-0(Hazardous Substances Data)

Usage

General Description

2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is a chemical compound with the molecular formula C9H8ClFNO. It is a member of the acetamide family and contains both a chlorine and a fluorine atom, as well as a methyl and phenyl group. 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is commonly used in pharmaceutical research and drug development, particularly in the synthesis of potential new medications. Its precise applications may vary, but it is valued for its ability to interact with biological systems and potentially influence physiological processes. As a result, 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is of interest to scientists and medical professionals seeking to better understand and treat various health conditions.

InChI:InChI=1/C9H9ClFNO/c1-6-2-3-8(7(11)4-6)12-9(13)5-10/h2-4H,5H2,1H3,(H,12,13)

Upstream product

• 452-80-2 2-fluoro-4-methylaniline 
• 79-04-9 chloroacetyl chloride 
• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 

Downstream Products

• 2377-28-8 N,N-diethyl-glycine-(2-fluoro-4-methyl-anilide) 

Relevant articles and documents

Synthesis, biological evaluation, and structure-activity relationships of new tubulin polymerization inhibitors based on 5-amino-1,2,4-triazole scaffold

Based on our previous research, thirty new 5-amino-1H-1,2,4-triazoles possessing 3,4,5-trimethoxyphenyl moiety were synthesized, and evaluated for antiproliferative activities. Among them, compounds IIa, IIIh, and IIIm demonstrated significant antiproliferative activities against a panel of tumor cell lines, and the promising compound IIIm dose-dependently caused G2/M phase arrest in HeLa cells. Furthermore, analogue IIa exhibited the most potent tubulin polymerization inhibitory activity with an IC50 value of 9.4 μM, and molecular modeling studies revealed that IIa formed stable interactions in the colchicine-binding site of tubulin, suggesting that 5-amino-1H-1,2,4-triazole scaffold has potential for further investigation to develop novel tubulin polymerization inhibitors with anticancer activity.

Discovery of new indole-based 1,2,4-triazole derivatives as potent tubulin polymerization inhibitors with anticancer activity

Thirty-six novel indole-based 1,2,4-triazole derivatives were designed and synthesized through the molecular hybrid strategy. The bioassay results revealed that 9p displayed excellent antiproliferative efficacies in the nanomolar range against HeLa cells. Importantly, the compound exhibited no obvious cytotoxic activity (IC50 > 100 μM) toward HEK-293, a normal human embryonic kidney cell line. Mechanism analysis indicated that 9p significantly arrested the cell cycle at the G2/M phase and induced apoptosis in HeLa cells in a dose-dependent manner. Further evidence demonstrated that the promising compound effectively inhibited tubulin polymerization with an IC50 value of 8.3 μM, and molecular docking studies revealed that 9p well occupied the colchicine-site in tubulin. The present study highlights that indole-triazole hybrids might be used as a promising scaffold to develop novel tubulin polymerization inhibitors for cancer treatment.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.